Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$75.96 USD

75.96
649,382

-0.46 (-0.60%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $75.96 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

REGN or TECH: Which Is the Better Value Stock Right Now?

REGN vs. TECH: Which Stock Is the Better Value Option?

Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?

Style Box ETF report for VBK

GSK or TECH: Which Is the Better Value Stock Right Now?

GSK vs. TECH: Which Stock Is the Better Value Option?

BIIB vs. TECH: Which Stock Is the Better Value Option?

BIIB vs. TECH: Which Stock Is the Better Value Option?

VRTX or TECH: Which Is the Better Value Stock Right Now?

VRTX vs. TECH: Which Stock Is the Better Value Option?

Techne (TECH) Lags Q1 Earnings and Revenue Estimates

Techne (TECH) delivered earnings and revenue surprises of -3.78% and 4.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

EXEL or TECH: Which Is the Better Value Stock Right Now?

EXEL vs. TECH: Which Stock Is the Better Value Option?

EXEL vs. TECH: Which Stock Is the Better Value Option?

EXEL vs. TECH: Which Stock Is the Better Value Option?

Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?

Style Box ETF report for VBK

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.

Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.

Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates

Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.

Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings

Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

3 Reasons Why Techne (TECH) Is a Great Growth Stock

Techne (TECH) possesses solid growth attributes, which could help it handily outperform the market.

MRNA vs. TECH: Which Stock Should Value Investors Buy Now?

MRNA vs. TECH: Which Stock Is the Better Value Option?

Wall Street Analysts Think Techne (TECH) Could Surge 30%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 29.7% in Techne (TECH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Techne (TECH) Lags Q4 Earnings Estimates

Techne (TECH) delivered earnings and revenue surprises of -0.49% and 0.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INCY vs. TECH: Which Stock Should Value Investors Buy Now?

INCY vs. TECH: Which Stock Is the Better Value Option?

Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?

Style Box ETF report for VBK

Does Techne (TECH) Have the Potential to Rally 39% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Techne (TECH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE